Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
City of Hope Medical Center
Massachusetts General Hospital
Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, Nanjing Medical University
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris
Genexine, Inc.
University of Colorado, Denver
Sanofi
Sanofi
Copenhagen University Hospital at Herlev
National Institutes of Health Clinical Center (CC)
Gustave Roussy, Cancer Campus, Grand Paris